Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label epcoritamab versus investigator's choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma
MOH_2021-01-18_009672Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma (2 arms), sponsored by Genmab. Primary endpoint: Overall survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on MOH_2021-01-18_009672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-18_009672.